SCHEMBL6235598

SCHEMBL6235598

COc1cccc(Oc2ccc3c(c2)c(O)c(C2=NS(=O)(=O)c4ccccc4N2)c(=O)n3CCC(C)C)n1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.56
HSD17B10 Q99714 1/20 0.56
CYP2C9 P11712 3/20 0.52
NR1I2 O75469 1/20 0.52
PDE5A O76074 2/20 0.34
LMNA P02545 1/20 0.33
ALDH1A1 P00352 2/20 0.32
MYLK Q15746 1/20 0.32
CHEK1 O14757 1/20 0.32
WEE1 P30291 1/20 0.32
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
KMT2A Q03164 1/20 0.31
HIF1A Q16665 2/20 0.31
MAPT P10636 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6235580 0.93 MAPK1 (0.55) MAPK1HSD17B10CYP2C9NR1I2ALDH1A1
SCHEMBL6240041 0.85 MAPK1 (0.59) MAPK1HSD17B10CYP2C9NR1I2LMNA
SCHEMBL6236659 0.84 MAPK1 (0.57) MAPK1HSD17B10CYP2C9NR1I2PDE5A
SCHEMBL6235652 0.83 MAPK1 (0.68) MAPK1HSD17B10CYP2C9NR1I2PDE5A
SCHEMBL6737830 0.83 MAPK1 (0.61) MAPK1HSD17B10CYP2C9NR1I2LMNA
SCHEMBL6739082 0.83 MAPK1 (0.67) MAPK1HSD17B10CYP2C9NR1I2ALDH1A1
SCHEMBL6232411 0.83 MAPK1 (0.67) MAPK1HSD17B10CYP2C9NR1I2LMNA
SCHEMBL6236709 0.82 MAPK1 (0.57) MAPK1HSD17B10CYP2C9NR1I2LMNA
SCHEMBL6234490 0.82 MAPK1 (0.64) MAPK1HSD17B10CYP2C9NR1I2LMNA
SCHEMBL6233871 0.82 MAPK1 (0.66) MAPK1HSD17B10CYP2C9NR1I2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP claimed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO claimed
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 MAPK1 3699/4885HSD17B10 1428/4885CYP2C9 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.